Treatment of malignancy by activation of the plasminogen system

Seminars in Thrombosis and Hemostasis

Volumn 28, Issue 1, 2002, Pages 5-17

  Zacharski, Leo R ^a   Ornstein, Deborah L ^a   Gabazza, Esteban C ^a   D'Alessandro Gabazza, Corina N ^a   Brugarolas, Antonio ^a   Schneider, Jeffrey ^a  

^a Department of Veterans Affairs Regional Office White River Junction   (United States)

Author keywords

Extracellular matrix; Fibrinolysis; Malignancy; Plasminogen activation

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FIBRINOLYTIC AGENT; FLUOROURACIL; GLYCERYL TRINITRATE; HEPARIN; MITOMYCIN C; MORPHINE; PLASMINOGEN; PLASMINOGEN ACTIVATOR; STREPTOKINASE; TEGAFUR; TRANEXAMIC ACID; UROKINASE; VINCRISTINE;

ADULT; AGED; ANIMAL MODEL; BLOOD CLOTTING; CANCER GROWTH; CANCER THERAPY; CASE REPORT; CELL INTERACTION; DOSE RESPONSE; ENDOMETRIUM CANCER; EXTRACELLULAR MATRIX; FEMALE; HEART INFARCTION; HODGKIN DISEASE; HUMAN; LIVER CARCINOMA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW;

ANIMALS; EXTRACELLULAR MATRIX; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMANS; NEOPLASMS; PLASMINOGEN; PLASMINOGEN ACTIVATORS;

EID: 0036191983     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-20560     Document Type: Review

References (121)

1. The plasminogen (fibrinolytic) system
2. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-uPAR-PAI-1 system
3. Modulation of tumor matrix by components of the plasminogen-plasmin system
4. Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin
5. Effect of human plasmin on the toxic effects and growth of blood-borne metastasis of the Brown-Pearce carcinoma and the V2 carcinoma of rabbit
6. Fibrinogen and the tumor problem
7. Techniques for inhibiting tumor metastases
8. Influence of heparin and defibrinase on transplantability of syngeneic tumors in mice
9. The effect of human fibrinolysin on pulmonary metastases of Walker 256 carcinosarcoma
10. Host factors influencing the development of metastases
11. Anticoagulants and the development of pulmonary metastases
12. Factors affecting the development of metastatic cancer. Effect of alterations in clotting mechanism
13. Trauma as a cause of localization of blood-borne metastases: Preventative effect of heparin and fibrinolysin
14. The cytotoxic effect of plasmin on Yoshida sarcoma cells
15. Decrease in pulmonary metastases: Potentiation of nitrogen mustard effect by heparin and fibrinolysin
16. Experimental studies of factors which influence hepatic metastases. VII. Effect of anticoagulants
17. Decrease of metastases of carcinosarcoma Walker 256 with irradiation and heparin or fibrinolytic agents
18. Irradiation and anticoagulant therapy to prevent pulmonary metastases of the V2 carcinoma in rabbits
19. Effect of fibrinolysis on spread of cancer
20. Blood anticoagulating system and malignant tumours
21. Mechanisms of metastasis production by blood-borne cancer cells
22. Mechanisms of establishment of tumor metastases
23. Experimental studies of the intravascular dissemination of ascetic V2 carcinoma cells in the rabbit, with special reference to fibrinogen and fibrinolytic agents
24. Basic and clinical studies on chemotherapy of cancer
25. Anticoagulants and tumor cell lodgment
26. The effect of human fibrinolysin on survival of carcinosarcoma 256 Walker cells in the blood
27. Fibrinogen and the interstitial behavior of cancer
28. The cytopathic effect of fibrinolytic agents and human placental fractions on HELA cells
29. Tumor metastasis and thrombosis, with special reference to thromboplastic and fibrinolytic activities of tumor cells
30. Inhibition of tumor implantation at sites of trauma by plasminogen activators
31. Effect of heparin, protamine, dicoumarol, streptokinase and epsilon-amino-n-caproic acid on the growth of human cells in vitro
32. Streptokinase inhibits pulmonary tumor seeding in an animal experimental model
33. Potentiation of cytotoxic drug effects. The significance of the combined therapy of cytotoxic drug and urokinase
34. Potentiation of cytotoxic drug effects. The significance of the combined therapy with dextran sulfate
35. Enhanced cell killing by thio-TEPA and urokinase
36. Coagulation and fibrinolysis system in tumor of the bladder. Effect of fibrinolytic and antifibrinolytic agents on N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced rat bladder tumor
37. Effect of radiation therapy combined with fibrinolytic agents on Ehrlich solid tumor in mice
38. Experimental studies on fibrinolysis in growth and spread of tumour
39. Studies on the circulation of experimental tumours
40. Fibrinogen metabolism in experimental tumours
41. Effect of fibrinolytic and antifibrinolytic therapy on the dissemination of experimental tumours
42. Effect of human serum plus streptokinase on spontaneous pulmonary metastases of Vx2 carcinomas transplanted in the maxillary sinus of the rabbit
43. Effect of urokinase on growth and metastases of rabbit V2 carcinoma
44. Effect of defibrination on tumor growth and response to chemotherapy
45. Modulation of tumor cell motility by plasmin
46. Peptides cleaved from fibrinogen by plasmin enhance the progression of L-1 sarcoma in BALB/c mice
47. Anticoagulants in the treatment of cancer
48. Combination of chemotherapy and proteolytic enzymes (an experimental approach)
49. Warfarin in the treatment of cancer
50. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism
51. Heparin and cancer
52. The rationale of anticoagulants in the treatment of cancer
53. Anticoagulation in the treatment of cancer in man
54. Anticoagulant therapy in patients with cancer
55. Fibrinolytic enzyme in the treatment of patients with cancer
56. The extranuclear control of mitosis and cell function. A theory of cellular organization
57. The effect of selective administration of anticancer agents in massive doses combined with fibrinolytic enzyme (urokinase) in a case of hepatic cancer
58. Tratamiento del carcinoma pulmonar de celulas pequeñas con urokinasa y quimioterapia intensiva. Resultados preliminares
59. Urokinase combination chemotherapy for treatment of small cell carcinoma of the lung
60. Urokinase combination chemotherapy in small cell lung cancer. A phase II study
61. Superior vena cava obstruction with carcinoma of the lung
62. Superior vena caval obstruction in carcinoma of lung
63. Superior vena caval obstruction with lung cancer
64. Early experience in a controlled clinical trial using streptokinase induced fibrinolysis during resections for colon and rectal carcinomas in an attempt to prevent hematogenous metastasis
65. Fibrinolytyc therapy of leukaemia
66. Adjuvant therapy of cancer via the cellular immune mechanism or fibrin by induced fibrinolysis and oral anticoagulants
67. Inhibition of antiplasmin, and effect of protease I in patients with leukaemia
68. The use of the proteolytic enzyme brinase to produce autocytotoxicity in patients with acute leukemia and its possible role in immunotherapy
69. Unblocking or activation of the cellular immune mechanism by induced proteolysis in patients with cancer
70. The effects of proteolysis on the human immune mechanism in cancer
71. B.C.G. plus protease I in malignant melanoma
72. Inhibition of antiplasmin, and fibrinolytic effect of protease in patients with cancer
73. Basic studies on combined use of anticancer agents and urokinase
74. Clinical use of urokinase combined with mitomycin-C on intraperitoneal perfusion therapy
75. Two clinical cases with stomach cancer significantly improved by combined use of 5-FU and urokinase
76. A clinical case with juvenile carcinomatous peritonitis improved by combined use of anticancer agent and urokinase
77. Clinical effect of combined therapy with mitomycin and urokinase on progressive uterine cancer
78. The prophylactic use of thio-TEPA and urokinase in transitional cell carcinoma of the bladder: A preliminary report
79. Experiences gained in the treatment of locally advanced breast cancer with various combined treatment. A clinical trial aimed at improving the effectiveness of cancer chemotherapy
80. Clinical evaluation of the combination therapy of various anticancer agents and urokinase: Comparison of tissue culture urokinase with urinary urokinase
81. Chemotherapy against pulmonary metastasis from uterine cervical carcinoma
82. Clinical use of urokinase on tumor of the bladder and ureteral stone
83. Combined therapy with lysosome labiliser (urokinase MDS) and anticancer agent
84. Combined therapy with lysosome labilizer and anticancer agent
85. Experimental and clinical studies on combined use with protease as method to potentiate the effect of anticancer agents
86. Method to potentiate the effect of anti-tumor-drugs. Meanings of urokinase combination
87. The role of induced fibrinolysis in cancer chemotherapy
88. Combined therapy with urokinase on terminal cancer
89. Cancer and fibrinolysis
90. Lysosome and chemotherapy. Combined therapy of mitomycin C and the lysosome labilizer plasmin
91. Anticancer therapy and its combination with lysosome labilizer
92. Biliary and pancreatic excretion of mitomycin C with special reference to the concomitant use of urokinase
93. Effects of urokinase on the transfer of 1-hexylcarbamoyl-5-fluorouracil (HCFU) into blood, bile and pancreatic juice
94. Anticancer agents in the treatment of two cases of carcinomatous peritonitis and combined therapy with urokinase
95. Treatment of cancer patients with infusions of plasmin
96. Pathways of coagulation/fibrinolysis activation in malignancy
97. Binding of anisoylated lys-plasminogen streptokinase activator complex to cells in culture
98. Annexin II and regulation of cell surface fibrinolysis
99. Studies of possible mechanisms for the effect of urokinase therapy in small cell carcinoma of the lung
100. The procoagulant state of the VX-2 tumor in rabbit lung in vivo: Relative accumulation of fibrinogen, prothrombin, plasminogen, antithrombin and heparin cofactor II within the tumor
101. Uptake of fibrinogen and fibrinolytic enzymes by neoplastic tissue
102. 131I-labeled porcine plasmin in man and dog
103. Fibrin and cancer
104. The role of fibrinolysis in disease processes
105. Molecular analysis of the role of the group A streptococcal cysteine protease, hyaluronic acid capsule, and M protein in a murine model of human invasive soft-tissue infection
106. Thrombolytic therapy with streptokinase stimulates collagen breakdown
107. Cell-cell and cell-extracellular matrix adhesion molecules communicate with growth factor receptors: An interactive signaling web
108. Growth factor receptor tyrosine kinases: Cell adhesion kinase family suggests a novel signaling mechanism in cancer
109. Spatial regulation and activity modulation of plasmin by high-affinity binding to the G domain of the alpha3 subunit of laminin-5
110. Distinct biological consequences of integrin alpha v beta 3-mediated melanoma cell adhesion to fibrinogen and its plasmic fragments
111. Angiogenesis and the fibrinolytic system
112. Towards improved thrombolytic therapy
113. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction
114. Activation of fibrinolysis and coagulation during interleukin 2 therapy
115. Haemostasis modifications during interleukin 2 therapy in advanced renal cell cancer
116. Enhancement of fibrinolysis in vitro by ultrasound
117. Mode of action of non-enzymatic activators of fibrinolysis: With reference to an anti-tumor agent and to dextran sulfate
118. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial